Search research articles
Contact Us
Filters
Showing results (11-20 of 25) with videos related to
Page
of 3
Sort By:
The Journal of Biological Chemistry
|
February 10, 2004
In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061: structural analysis indicates different resistance mechanisms
Chao Lin, Kai Lin, Yu-Ping Luong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 24, 2025
MTA-Cooperative PRMT5 Inhibitors are Efficacious in MTAP-Deleted Malignant Peripheral Nerve Sheath Tumor Models
Xiaochun Zhang, Dana C Borcherding, Minjie Zhang, et al.
Journal of Medicinal Chemistry
|
April 10, 2024
Discovery of TNG908: A Selective, Brain Penetrant, MTA-Cooperative PRMT5 Inhibitor That Is Synthetically Lethal with <i>MTAP</i>-Deleted Cancers
Kevin M Cottrell, Kimberly J Briggs, Douglas A Whittington, et al.
Bioorganic & Medicinal Chemistry Letters
|
May 2, 2025
Discovery of TNG-6132, a potent, selective, and orally bioavailable USP1 inhibitor
Scott Throner, Tianshu Feng, Jannik N Andersen, et al.
Molecular Cancer Therapeutics
|
January 31, 2025
Characterization of TNG348: A Selective, Allosteric USP1 Inhibitor That Synergizes with PARP Inhibitors in Tumors with Homologous Recombination Deficiency
Antoine Simoneau, Charlotte B Pratt, Hsin-Jung Wu, et al.
ACS Medicinal Chemistry Letters
|
June 6, 2014
Discovery of Thienoimidazole-Based HCV NS5A Genotype 1a and 1b Inhibitors
Simon Giroux, Jinwang Xu, T Jagadeeswar Reddy, et al.
Bioorganic & Medicinal Chemistry Letters
|
January 18, 2015
Discovery of thienoimidazole-based HCV NS5A inhibitors. Part 1: C2-symmetric inhibitors with diyne and biphenyl linkers
Simon Giroux, Darius Bilimoria, Caroline Cadilhac, et al.
Cancer Research
|
June 10, 2026
TNG917 is a Potent and Selective Inhibitor of Histone Lysine Methyltransferases EHMT1/2 that Enhances Anti-Tumor Immunity and Immunotherapy Efficacy
Alvin Ziying Lu, Brian B Haines, Wenhai Zhang, et al.
Bioorganic & Medicinal Chemistry Letters
|
January 19, 2015
Discovery of thienoimidazole-based HCV NS5A inhibitors. Part 2: non-symmetric inhibitors with potent activity against genotype 1a and 1b
Simon Giroux, Darius Bilimoria, Caroline Cadilhac, et al.
Molecular Cancer Therapeutics
|
October 13, 2022
Ubiquitinated PCNA Drives USP1 Synthetic Lethality in Cancer
Antoine Simoneau, Justin L Engel, Madhavi Bandi, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 25) with videos related to
Sort By:
Page
of 3
The Journal of Biological Chemistry
|
February 10, 2004
In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061: structural analysis indicates different resistance mechanisms
Chao Lin, Kai Lin, Yu-Ping Luong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 24, 2025
MTA-Cooperative PRMT5 Inhibitors are Efficacious in MTAP-Deleted Malignant Peripheral Nerve Sheath Tumor Models
Xiaochun Zhang, Dana C Borcherding, Minjie Zhang, et al.
Journal of Medicinal Chemistry
|
April 10, 2024
Discovery of TNG908: A Selective, Brain Penetrant, MTA-Cooperative PRMT5 Inhibitor That Is Synthetically Lethal with <i>MTAP</i>-Deleted Cancers
Kevin M Cottrell, Kimberly J Briggs, Douglas A Whittington, et al.
Bioorganic & Medicinal Chemistry Letters
|
May 2, 2025
Discovery of TNG-6132, a potent, selective, and orally bioavailable USP1 inhibitor
Scott Throner, Tianshu Feng, Jannik N Andersen, et al.
Molecular Cancer Therapeutics
|
January 31, 2025
Characterization of TNG348: A Selective, Allosteric USP1 Inhibitor That Synergizes with PARP Inhibitors in Tumors with Homologous Recombination Deficiency
Antoine Simoneau, Charlotte B Pratt, Hsin-Jung Wu, et al.
ACS Medicinal Chemistry Letters
|
June 6, 2014
Discovery of Thienoimidazole-Based HCV NS5A Genotype 1a and 1b Inhibitors
Simon Giroux, Jinwang Xu, T Jagadeeswar Reddy, et al.
Bioorganic & Medicinal Chemistry Letters
|
January 18, 2015
Discovery of thienoimidazole-based HCV NS5A inhibitors. Part 1: C2-symmetric inhibitors with diyne and biphenyl linkers
Simon Giroux, Darius Bilimoria, Caroline Cadilhac, et al.
Cancer Research
|
June 10, 2026
TNG917 is a Potent and Selective Inhibitor of Histone Lysine Methyltransferases EHMT1/2 that Enhances Anti-Tumor Immunity and Immunotherapy Efficacy
Alvin Ziying Lu, Brian B Haines, Wenhai Zhang, et al.
Bioorganic & Medicinal Chemistry Letters
|
January 19, 2015
Discovery of thienoimidazole-based HCV NS5A inhibitors. Part 2: non-symmetric inhibitors with potent activity against genotype 1a and 1b
Simon Giroux, Darius Bilimoria, Caroline Cadilhac, et al.
Molecular Cancer Therapeutics
|
October 13, 2022
Ubiquitinated PCNA Drives USP1 Synthetic Lethality in Cancer
Antoine Simoneau, Justin L Engel, Madhavi Bandi, et al.
Page
of 3